Clinical trials located in

Clermont-Ferrand

Clermont-Ferrand city is located in France. Currently, 20 clinical trials are being conducted in this city.

Clermont-Ferrand, nestled in central France, is renowned for its rich history and vibrant culture. This city is the birthplace of mathematician Blaise Pascal and is encircled by the Chaîne des Puys, a chain of volcanoes. Its Gothic cathedral, built from black lava stone, stands as a testament to its medieval past. Clermont-Ferrand also hosts the International Short Film Festival, attracting filmmakers and enthusiasts globally. Additionally, it’s a hub for the Michelin tire company, significantly influencing the city’s development and economy.

  • CT-EU-00116695

    Study on combining two drugs – Fianlimab and Cemiplimab in patients with previously untreated melanoma

    This study examines two drugs, fianlimab and cemiplimab, given together for the treatment of melanoma. The main goal is to see how effective this drug combination is in treating melanoma compared with pembrolizumab, which is already approved for the treatment of melanoma in adults. The study will also look at whether there are any differences in the effects of these experimental drugs in adolescents and adults.

    Scientists also want to learn about other key issues: what side effects may occur from taking these experimental drugs, how much of the drugs enter the bloodstream over time, and whether the body produces antibodies to the drugs that could make them less effective or cause side effects. They will also check whether taking medications improves patients’ quality of life. Fianlimab and cemiplimab will be administered by intravenous infusion, and pembrolizumab will be administered by intravenous infusion.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyNetherlandsPolandRomaniaSpainUnited Kingdom
  • Exploring a new treatment combination for rheumatoid arthritis: baricitinib plus anti-TNF

    This clinical trial is focused on finding a more effective treatment for people with Rheumatoid Arthritis (RA) who haven’t responded well to previous therapies. The study is comparing two different approaches: one group will receive a combination of baricitinib treatment and an anti-TNF therapy (adalimumab), while the other group will receive baricitinib along with a placebo. The main goal is to see which group shows a greater improvement in their RA symptoms, specifically looking for a 50% improvement in symptoms, known as an ACR 50 response, after 24 weeks from the start of the treatment.

    Baricitinib is a medication that targets certain pathways in the body’s immune system to reduce inflammation and pain in RA. Anti-TNF therapy, like adalimumab, works by blocking the action of a protein in the body that causes inflammation. By combining these two treatments, researchers hope to see a more significant improvement in RA symptoms than with baricitinib alone.

    The trial is important because it aims to provide a new option for patients with RA who have not found relief with current treatments. It’s designed to test the safety and effectiveness of using these two different types of medications together.

    France
  • Study on Ravulizumab’s effect on Immunoglobulin A Nephropathy

    The study is looking into the effectiveness of a medication called ravulizumab for adults who have a kidney condition known as Immunoglobulin A Nephropathy (IgAN). This condition can lead to kidney damage over time, and the study aims to find out if ravulizumab can help reduce the amount of protein lost in urine—a common problem in IgAN—and slow down the decrease in kidney function.

    In this study, about 450 participants who are at a high risk of their disease getting worse will be chosen. These participants must have been on stable treatment for their IgAN for at least three months before the study starts. They will then receive either ravulizumab or a placebo, which is a treatment with no active drug, through an IV infusion based on their weight. The main goal is to see if those who receive ravulizumab have a significant improvement in their condition compared to those who receive the placebo.

    The study will have two main checkpoints. The first one, at Week 34, will check how much protein is in the urine, and the second one, at Week 106, will assess how well the kidneys are filtering waste from the blood. Additionally, a smaller group of participants with more advanced kidney issues will receive ravulizumab to further explore its effects.

    After the study ends at Week 106, participants will have the option to continue receiving ravulizumab in a follow-up period to see how long-term treatment affects their condition. This study is a chance for people with IgAN to potentially slow down their disease progression and improve their quality of life.

  • Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    AustriaBelgiumFinlandFranceGermanyHungaryItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Ceralasertib & durvalumab vs docetaxel in advanced lung cancer study

    This is an open-label study titled LATIFY, which means everyone will know the type of treatment they are receiving. The study team is looking into a specific type of lung cancer, called Non-Small Cell Lung Cancer (NSCLC) which did not get better after previous treatments. Two treatments will be tested, a new combination of ceralasertib plus durvalumab, compared to a commonly used treatment, docetaxel. Doctors will track participants’ health over time to see which treatment helps people live longer. Understanding the results will help doctors responsibly give the best treatment for patients with this type of lung cancer.

    BelgiumFranceGermanyHungaryItalyNetherlandsPolandRomaniaSpainUnited Kingdom
  • New lung cancer study: testing osimertinib before surgery

    The aim of this clinical trial is to evaluate the effectiveness of osimertinib, a drug that specifically targets the EGFR mutation, in patients with resectable non-small cell lung cancer. The study will involve three groups: one will receive standard chemotherapy, the second will receive a combination of osimertinib and chemotherapy, and the third will receive osimertinib alone. This phase III trial focuses on patients with a specific genetic mutation (EGFRm) in lung cancer. Key outcomes measured include tumor removal rate, survival rates and overall quality of life. The aim is to improve the standard of pre-operative treatment, which could potentially lead to better outcomes for lung cancer patients. The study also aims to understand the impact of osimertinib on this disease, particularly when combined with traditional chemotherapy, which will provide a comprehensive picture of potential benefits and risks.

    AustriaBulgariaFranceGermanyItalyPolandSpainUnited Kingdom
  • Study of alpelisib and fulvestrant for advanced breast cancer treatment

    This trial is looking at the effects of the combined use of two drugs, alpelisib and fulvestrant, in treating patients who have advanced breast cancer. The cancer should be HR-positive and HER2-negative, and have a specific mutation (PIK3CA). If the patients already underwent certain other treatments like CDK4/6 Inhibitors and aromatase Inhibitors, but the cancer has progressed, they could join this trial. Doctors will be able to compare the results of patients taking alpelisib and fulvestrant together, with those taking fulvestrant with a placebo, They aim to check which combination works better in delaying the advance of cancer or in improving a patient’s life duration.

    BelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyPolandPortugalRomaniaSlovakiaSpain
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Comparing atogepant and topiramate for migraine prevention

    In this study, a comparison is being made between two different medicines aimed at preventing migraines in adults. Migraines manifest as severe headaches on one side of the head, accompanied by symptoms such as nausea, throbbing pain, or sensitivity to light and sound. The two medicines under comparison are named atogepant and topiramate. Atogepant is currently employed for migraine prevention in individuals experiencing migraines from 0 to 14 days per month, and the study seeks to evaluate its potential broader application. Topiramate is already widely utilized for migraine prevention. Participants in this study will be divided into two groups: one group will be administered atogepant, while the other will receive topiramate for a duration of 24 weeks. Following this period, those eligible to continue will all receive atogepant for an additional 52 weeks. The study will assess their progress and monitor any potential side effects.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyPolandPortugalUnited Kingdom
  • Study on Tolebrutinib’s ability to delay disability progression in multiple sclerosis

    This is a study that involves a specific type of multiple sclerosis (MS) called primary progressive multiple sclerosis (PPMS). In this study, a drug called SAR442168, also known as Tolebrutinib, will be tested against a placebo. The main purpose of the study is to see if this drug can slow down the progression of disability in PPMS. The researchers will also look at the drug’s effect on clinical markers, brain images (MRI), thinking abilities, physical function, and quality of life. They will also consider the safety and tolerability of this drug. How long each person will take the drug can vary, but it will be somewhere between 12 and 60 months.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSpainSwedenUnited Kingdom
  • Breast cancer treatment study: Dato-DXd and durvalumab

    This clinical trial is a comprehensive study aimed at evaluating the effectiveness and safety of advanced treatments for breast cancer, specifically targeting triple-negative and hormone receptor-low/HER2-negative types. The study involves two groups of participants. One group will receive a combination of Dato-DXd and durvalumab as a neoadjuvant (pre-surgery) treatment, followed by durvalumab as an adjuvant (post-surgery) therapy, with or without additional chemotherapy. The other group will be treated with pembrolizumab plus chemotherapy as both neoadjuvant and adjuvant therapies. The goal is to see which method is better at treating the cancer. Additional objectives include evaluating overall survival, distant disease-free survival, and participant-reported outcomes related to symptoms, physical function, fatigue, and quality of life.

    AustriaBelgiumBulgariaFranceGermanyHungaryItalySpainUnited Kingdom
  • Effects of new drug on metastatic prostate cancer

    This trial studies the effect of AZD5305 plus physician-chosen hormonal agents versus placebo in men with metastatic castration-sensitive prostate cancer (mCSPC). Around 1800 adult men with mCSPC are being enrolled and divided into two groups: those receiving AZD5305 and those receiving a placebo, both alongside standard hormonal treatments. Safety and treatment effects will be monitored. The goal is to find out if this new drug combination helps patients live longer without their cancer getting worse.

    AustriaBelgiumFinlandFranceGermanyHungaryItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Breast cancer treatment study: camizestrant vs. standard therapy

    This study is looking at a new drug called camizestrant for adults with a certain type of early breast cancer (ER+/HER2-). It compares camizestrant with standard endocrine therapies like tamoxifen and aromatase inhibitors in patients who have already received 2–5 years of endocrine therapy. The study’s focus is on preventing cancer recurrence over 60 months. About 4300 participants are involved, and the trial features an open-label design, meaning everyone knows which treatment they are receiving. The main goal is to check how well the camizestrant works in comparison to standard treatments.

    AustriaBelgiumBulgariaCzechiaFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom
  • Evaluation of the effectiveness of combined therapy in the treatment of bladder cancer with muscle invasion

    This clinical study, known as the VOLGA trial, is for bladder cancer patients who cannot or refuse to take Cisplatin. Two new therapy combinations are being tested. The first combines Durvalumab, Tremelimumab, and Enfortumab Vedotin. The second partners Durvalumab with Enfortumab Vedotin only. Patients receive these drugs both before and after having bladder surgery. This study wants to involve about 830 patients and will assign them blindly to the therapy combinations. Patients will receive the blend for three cycles, with more Durvalumab treatments after surgery. We want to track if the cancer is eradicated after surgery, when the cancer appears again, the survival rate, unwanted effects, and the patients’ well-being. Taking part in this study might require commitment for approximately 3-5 years, with follow-ups to monitor the patient’s progress.

    AustriaFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Testing a new trio of drugs for advanced and metastatic breast cancer

    This study, known as CAPItello-292, is testing a new combination of drugs to see if it can help treat advanced or spreading breast cancer. The drugs include one called capivasertib along with two others known as CDK4/6 inhibitors and another drug called fulvestrant. The study wants to see how well these work together and how safe they are. Firstly, they need to decide on the best dose of these drugs to use together. Then, the main part of the study will compare these drugs with the usual treatment – either of the CDK4/6 inhibitors with fulvestrant — to see which is better. Scientists will check the blood of the patients to see how much of the drugs are present. They also want to see how many people have side effects and how severe these are. Patients’ health will also be monitored, including heart tests, blood tests and checking vital signs. The ultimate goal is to see if this new treatment can slow down the growth of the cancer, or even shrink it. In simpler words, this is a study for people with a type of advanced breast cancer. It’s testing three drugs together — capivasertib, a CDK4/6 inhibitor, and fulvestrant. This study is made up of two parts. The first part is to decide on the right amount of these drugs to give at the same time. Then, they’ll test this against the usual treatment to see if it’s better. They’ll use blood tests to check how much of the drugs are in the body and will carefully watch for any side effects. They’ll also keep a close eye on people’s health overall. The main aim is to see if this new combination can stop the cancer from getting worse. The CAPItello-292 trial is aimed at patients with serious breast cancer that has started to spread. In this research, a new blend of three medicines, capivasertib, a CDK4/6 inhibitor, and fulvestrant, is being evaluated. First, researchers want to figure out the optimal dosing of these drugs when taken together. Then they’ll compare this combination to the standard treatment to see if it provides any additional benefits. They’ll take blood tests to track the amount of medication and continuously monitor for any potential side effects. The end goal is to see if this new drug mixture can slow or even decrease the growth of the cancer.

    BelgiumDenmarkFranceGermanyItalyPolandSpainSwedenUnited Kingdom
  • Trial for new lung cancer treatment

    This study evaluated the effectiveness of telisotuzumab Vedotin, an investigational drug, in adults with a specific type of lung cancer called non-squamous non-small cell lung cancer (NSCLC), which has MET amplification. Participants will receive the drug as an intravenous infusion every two weeks and will be closely monitored for changes in tumor activity. The study will involve patients with this particular type of lung cancer, focusing on those that have not been previously treated due to advanced or metastatic disease. Regular medical evaluations, blood tests and monitoring for side effects are part of a study to understand the effects of the drug.

    FranceGermanyItaly
  • A new trial of treatment of amyotrophic lateral sclerosis with masitinib and riluzole

    This clinical trial is investigating the effects of masitinib in combination with riluzole on patients with ALS, a progressive neurodegenerative disease. The study aims to determine if masitinib can provide neuroprotection and slow the disease’s progression by modulating neuroinflammatory responses in the central and peripheral nervous systems. Participants will initially receive masitinib orally at a starting dose, which will be adjusted based on safety evaluations. The treatment’s efficacy will be monitored through clinical assessments, including ALS functional rating scales, quality of life questionnaires, and physical tests like breathing capacity and muscle strength. The trial is double-blind, meaning neither participants nor investigators know who receives masitinib or the placebo, ensuring unbiased results. The ultimate goal is to discover a treatment that can improve survival and life quality for those afflicted with ALS.

    BelgiumDenmarkFranceGermanyGreeceItalyNorwayPolandPortugalSloveniaSpainSweden
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain

See more clinical trials in other cities in France:

.